Press release
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”)
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2022. “Alzheimer’s disease represents a growing burden to healthcare systems and societies worldwide. This disease is often multifactorial and complex in nature, and we believe that our precision medicine platform and novel central nervous system mechanism improve the chance of clinical success. We are pleased by the results of the placebo-controlled Phase 2b/3 Alzheimer’s disease trial which data suggest that ANAVEX®2-73 (blarcamesine), an orally available, small-molecule activator of the upstream sigma-1 receptor (SIGMAR1), is pivotal to restoring neural cell homeostasis and promoting neuroplasticity and might be at the forefront of biomarker-guided pathway-based targeted precision medicine drug development,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We look forward to presenting the complete dataset of the study as well as other long-term study data of the other programs, including Parkinson’s disease dementia and Rett syndrome. With a deep portfolio of promising therapies, we believe that Anavex remains well positioned to address the urgent needs of patients affected by neurodegenerative and rare neurodevelopmental diseases.” Key Near Term Pipeline Updates: Alzheimer’s disease: Full data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 clinical trialParkinson’s disease dementia: Data of 48-week OLE Phase 2 studyParkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused clinical trialFragile X: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trialSchizophrenia: Initiation of ANAVEX®3-71 Phase 2 clinical trialNew Rare disease: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trialPublications: Several clinical publications involving ANAVEX®2-73, ANAVEX®3-71 and Rett syndrome Burden of Illness study Recent Business Highlights: On February 2n...